---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Indication"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Indication. Topics: Population of the pivotal AMPLITUDE trial: primary AMKD with severe proteinuria and no kidney disease-causing comorbidities, Indication named for a potential accelerated approval: patients with AMKD, Age range in AMPLITUDE: 10 to 65 years, Indications named in regulatory designations: APOL1-mediated FSGS (FDA) and AMKD (EMA), and 1 further topic. 5 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/indication"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Indication

<a id="heading-2.1.2.5"></a>

## 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

### Population of the pivotal AMPLITUDE trial: primary AMKD with severe proteinuria and no kidney disease-causing comorbidities

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The phase 2/3 randomized, placebo-controlled AMPLITUDE trial is evaluating the effects of IXP on preserving kidney function and reducing proteinuria in non-diabetic persons with AMKD and severe proteinuria (UPCR ≥0.7 to <10g/g).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-2.1.2.5-2"></a>

### Indication named for a potential accelerated approval: patients with AMKD

> “If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.5-3"></a>

### Age range in AMPLITUDE: 10 to 65 years

> “Ages Eligible for Study 10 Years to 65 Years (Child, Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.5-4"></a>

### Indications named in regulatory designations: APOL1-mediated FSGS (FDA) and AMKD (EMA)

> “The U.S. Food and Drug Administration (FDA) has granted inaxaplin Rare Pediatric Disease Designation (RPD) and Breakthrough Therapy Designation (BTD) for APOL1-mediated focal segmental glomerulosclerosis (FSGS). The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

| Field | Quoted record |
| --- | --- |
| Intended use | “Treatment of apolipoprotein L1-mediated kidney disease” |

Source: [EMA orphan designation EU/3/22/2697 (2022)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2697)

<a id="topic-2.1.2.5-5"></a>

### Indication expansion studied in AMPLIFIED: AMKD with modest proteinuria or with type 2 diabetes

> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”
> “evaluates inaxaplin as a treatment for people with AMKD with moderate proteinuria, or with AMKD and type 2 diabetes, two populations that are not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

> “An FDA label covering the two arms in Amplified would add about 100,000 patients to the target population.”

Source: [Fierce Biotech (2026)](https://www.fiercebiotech.com/biotech/vertexs-midstage-data-amplify-kidney-disease-market-opportunity)

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
